Low-density lipoprotein oxidation

Italian Heart Journal

Volumn 2, Issue 12, 2001, Pages 867-872

  Iuliano, Luigi ^a   Micheletta, Fausta ^a   Violi, Francesco ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

Atherosclerosis; Free radicals; Low density lipoproteins; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; AMINO ACID; ANTIOXIDANT; APOLIPOPROTEIN B; CELL RECEPTOR; CHOLESTEROL; CRESOL; DIPHENYLENEDIAMINE; FREE RADICAL; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; PROBUCOL; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; FOAM CELL; HUMAN; LIPID OXIDATION; MACROPHAGE; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN STRUCTURE;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS, LDL; OXIDATION-REDUCTION;

EID: 0035572708     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Low density lipoprotein oxidation and its pathobiological significance
2. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions
3. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions
4. The pathogenesis of atherosclerosis
5. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis
6. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition
7. Introduction, structure and metabolism of plasma lipoproteins
8. The role of lipid peroxidation and antioxidants in oxidative modification of LDL
9. Enhanced macrophage uptake of low density lipoprotein after self-aggregation
10. Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages
11. Lipoprotein-antibody immune complexes. Their catabolism and role in foam cell formation
12. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation
13. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates
14. Phagocytosis of lipase-aggregated low density lipoprotein promotes macrophage foam cell formation. Sequential morphological and biochemical events
15. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I
16. On the pathogenesis of atherosclerosis: Enzymatic transformation of human low density lipoprotein to an atherogenic moiety
17. Phagocytosis of aggregated lipoprotein by macrophages: Low density lipoprotein receptor-dependent foam-cell formation
18. Low density lipoprotein undergoes oxidative modification in vivo
19. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man
20. Lipoproteins in normal and atherosclerotic aorta
21. 7 beta-hydroperoxycholest-5-en-3 beta-ol, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein
22. Localization of distinct F2-isoprostanes in human atherosclerotic lesions
23. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum
24. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis
25. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma
26. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody
27. Single LDL apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans
28. LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth, and compensatory vessel enlargement in coronary arteries of miniature pigs
29. LDL- is a lipid hydroperoxide-enriched circulating lipoprotein
30. Protein oxidation in aging, disease, and oxidative stress
31. 2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins
32. Oxidation of low-density lipoprotein by hemoglobin stems from a heme-initiated globin radical: Antioxidant role of haptoglobin
33. LDL-platelet interaction under oxidative stress induces macrophage foam cell formation
34. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetylated low density lipoproteins
35. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic
36. Structures and functions of multiligand lipoprotein receptors: Macrophage scavenger receptors and LDL receptor-related protein (LRP)
37. Molecular flypaper, host defense, and atherosclerosis. Structure, binding properties, and functions of macrophage scavenger receptors
38. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection
39. CD36 is a receptor for oxidized low density lipoprotein
40. Expression cloning of SR-BI, a CD36-related class B scavenger receptor
41. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68
42. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein
43. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins
44. Biologically modified LDL increases the adhesive properties of endothelial cells
45. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937
46. Activation of soluble guanylate cyclase by nitrovasodilators is inhibited by oxidized low-density lipoprotein
47. Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation
48. Hypochlorite modified LDL are a stronger agonist for platelets than copper oxidized LDL
49. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells
50. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins
51. F(2)-isoprostanes: Sensitive and specific non-invasive indices of lipid peroxidation in vivo
52. Oxysterols and atherosclerosis
53. Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production
54. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL
55. Induction of interleukin-1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid
56. The influence of oxidatively modified low density lipoproteins on expression of platelet-derived growth factor by human monocyte-derived macrophages
57. Vitamin E and heart disease: Basic science to clinical intervention trials
58. Vitamin E, atherosclerosis and thrombosis
59. 2α is increased in hypercholesterolemia
60. 2α and platelet activation in diabetes mellitus. Effects of improved metabolic control and vitamin E supplementation
61. Angioplasty increases coronary sinus F2-isoprostane formation: Evidence for in vivo oxidative stress during PTCA
62. Local amplification of platelet function by 8-epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms
63. Vascular biology of the isoprostanes
64. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk
65. Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque: Effect of vitamin E supplementation
66. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study
67. Vitamin E supplementation and cardiovascular events in high-risk patients
68. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
69. Vitamin E supplementation and cardiovascular events in high-risk patients
70. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial
71. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice
72. Measurement of lipid-soluble vitamins: Further adjustment needed?
73. Bioavailability of vitamin E as function of food intake in healthy subjects. Effects on plasma peroxide-scavenging activity and cholesterol-oxidation products